Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 81, Issue 1, 2008, Pages 42-49

  Kim, Hae Jin ^a   Kim, Soo Kyung ^b   Shim, Wan Sub ^c   Lee, Jae Hyuk ^d   Hur, Kyu Yeon ^d   Kang, Eun Seok ^d   Ahn, Chul Woo ^d   Lim, Sung Kil ^d   Lee, Hyun Chul ^d   Cha, Bong Soo ^d  

^a Ajou University School of Medicine   (South Korea)

^b Department of Biochemistry   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Insulin sensitivity; Leptin; Rosiglitazone; Subcutaneous adiposity

Indexed keywords

ADIPONECTIN; INSULIN; LEPTIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CORRELATION ANALYSIS; DIABETIC PATIENT; ECHOGRAPHY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SUBCUTANEOUS FAT; TREATMENT DURATION;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; WAIST-HIP RATIO;

EID: 44649123582     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.02.001     Document Type: Article

References (28)

1. Smith S.A. Peroxisomal proliferator activated receptors (PPARs): molecular targets for hypolipidaemic agents and insulin sensitizers. Pharmacol. Rev. Commun. 8 (1996) 57-64
2. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 374 (1995) 425-432
3. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl. J. Med. 334 (1996) 292-295
4. Considine R.V., and Caro J.F. Leptin and the regulation of body weight. Int. J. Biochem. Cell. Biol. 29 (1997) 1255-1272
5. Nolan J.J., Olefsty J.M., Nyce M.R., Considine R.V., and Caro J.F. Effect of troglitazone on leptin production: Studies in vitro and in human subjects. Diabetes 45 (1996) 1276-1278
6. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L.J., and DeFronzo R.A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 4312-4319
7. Shimizu H., Tsuchiya T., Sato N., Shimomura Y., Kobayashi I., and Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diab. Care 21 (1998) 1470-1474
8. Considine R.V. Regulation of leptin production. Rev. Endocr. Metab. Disord. 2 (2001) 357-363
9. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifugation. Clin. Chem. 18 (1972) 499-502
10. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
11. Suzuki R., Watanabe S., Hirai Y., Akiyama K., Nishide T., Matsushima Y., et al. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am. J. Med. 95 (1993) 309-314
12. Armellini F., Zamboni M., Rigo L., Bergamo-Andreis I.A., Robbi R., De Marchi M., et al. Sonography detection of small intra-abdominal fat variations. Int. J. Obes. Relat. Metab. Disord. 15 (1991) 847-852
13. Kim S.K., Kim H.J., Hur K.Y., Choi S.H., Ahn C.W., Lim S.K., et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am. J. Clin. Nutr. 79 (2004) 593-599
14. Kallen C.B., and Lazar M.A. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5793-5796
15. Hollenberg A.N., Susulic V.S., Madura J.P., Zhang B., Moller D.E., Tontonoz P., et al. Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferators-activated receptor-γ on the leptin promoter. J. Biol. Chem. 272 (1997) 5283-5290
16. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferators-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100 (1997) 3149-3153
17. Edwards P.A. Fatty livers and reduced adipose tissue, who wants it?. J. Clin. Invest. 98 (1996) 1506-1507
18. Carey D.G., Cowin G.J., Galloway G.J., Jones N.P., Richards J.C., Biswas N., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes. Res. 10 (2002) 1008-1015
19. Van Harmelen V., Reynisdottir S., Eriksson P., Thörne A., Hoffstedt J., Lönnqvist F., et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47 (1998) 913-917
20. Roemmich J.N., Clark P.A., Berr S.S., Mai V., Mantzoros C.S., Flier J.S., et al. Gender differences in leptin levels during puberty are related to the subcutaneous fat depot and sex steroids. Am. J. Physiol. 275 (1998) E543-E551
21. Williams L.B., Fawcett R.L., Waechter A.S., Zhang P., Kogon B.E., Jones R., et al. Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J. Clin. Endocrinol. Metab. 85 (2000) 2678-2684
22. Patel N.G., Holder J.C., Smith S.A., Kumar S., and Eggo M.C. Differential regulation of lipogenesis and leptin production by independent signaling pathways and rosiglitazone during human adipocyte differentiation. Diabetes 52 (2003) 43-50
23. Caro J.F., Sinha M.K., Kolaczynski J.W., Zhary P.L., and Considine R.V. Leptin: the tale of an obesity gene. Diabetes 45 (1996) 1455-1462
24. Mueller W.M., Gregoire F.M., Stanhope K.L., Mobbs C.V., Mizuno T.M., Warden C.H., et al. Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. Endocrinology 139 (1998) 551-558
25. Pasman W.J., Westerterp-Plantenga M.S., and Saris W.H.M. The effect of exercise training on leptin levels in obese males. Am. J. Physiol. Endocrinol. Metab. 274 (1998) E280-E286
26. Kim Y.M., Cha B.S., Kim D.J., Choi S.H., Kim S.K., Ahn C.W., et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 67 (2005) 43-52
27. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
28. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 279 (2004) 12152-12162